Where does Celgene Quanticel Research, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Celgene Quanticel Research, Inc. ranks #3,558 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Celgene Quanticel Research, Inc. hold?

Celgene Quanticel Research, Inc. holds 103 US utility patents granted between 2016 and 2024, spanning 6 technology areas.

What is Celgene Quanticel Research, Inc.'s Innovation Score?

Celgene Quanticel Research, Inc. has an Innovation Score of 37.3 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Celgene Quanticel Research, Inc. focus on?

Celgene Quanticel Research, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 99 patents. Grants appear in 6 CPC subclasses total.

Is Celgene Quanticel Research, Inc.'s patent grant rate increasing or decreasing?

Celgene Quanticel Research, Inc.'s recent grant velocity is -37% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Celgene Quanticel Research, Inc.'s patents?

Celgene Quanticel Research, Inc.'s patents average 18.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Celgene Quanticel Research, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Celgene Quanticel Research, Inc.

USPTO PatentsView assignee record - 103 granted patents across 6 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Celgene ranks #3,558 of 49,997 tracked US assignees by granted-patent volume, with 103 patents across 6 technology areas.

#3,558
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.3/100): 18.4
avg claims per patent: -37%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3558 · US Corporation #3,558 · 103 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 103 grants
TOP-DECILE #3,558/49,997
PHOTO-FINISH Crayola
CPC-NARROW C07D · 6 areas
INNOV-THIN 37.3/100
CLAIMS-RICH 18.4 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -37% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Crayola LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Celgene Quanticel… · this assignee

37
Spal Automotive S R L · near

37
Zhuhai Seine… · near

37
All Plastic · near

37
Bbpos · near

37
3D Lighting… · lowest

7

What this shows Celgene's Innovation Score is 37.3/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Celgene's grants concentrate

Celgene Quanticel Research, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 96.1% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2018 (23 grants) versus a trough of 3 in 2016. By volume, Celgene sits between Weka.IO Ltd. and Fastly, Inc..

Celgene's three-year grant acceleration

From 2019–2021 to 2022–2024, Celgene Quanticel Research, Inc. moved from 47 to 11 grants (0.23x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #3,061. See the growth leaderboard.

Weka IO

104
Wilson

104
Xiamen Pvtech

104
Yuyama Mfg

104
Crayola

103
Evogene

103
Flos S P A

103
Fastly

103
Celgene Quanticel… ◀

103

What this shows Celgene holds 103 patents at rank #3,558, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Celgene

By rank, the assignees closest to #3,558 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Celgene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Celgene, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (37 here).

Zhuhai Seine Technology Co., Ltd. 37 Spal Automotive S.R.L. 37 All Plastic, Inc. 37 Bbpos Limited 37

Similar claim depth

Nearest assignees by average claims per patent (18.4 here).

Orbital Research Inc. 18.4 avg Smartsky Networks LLC 18.4 avg InterDigital Madison Patent Holdings, SAS 18.4 avg Tusimple, Inc. 18.4 avg

Celgene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Celgene Quanticel Research, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	3	2.9%
2017	19	18.4%
2018	23	22.3%
2019	18	17.5%
2020	22	21.4%
2021	7	6.8%
2022	3	2.9%
2023	3	2.9%
2024	5	4.9%

Which technologies does Celgene Quanticel Research, Inc. patent most?

C07D - Heterocyclic Compounds 99

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 97

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 46

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 10

C12Y - Enzymes 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#3,558

of 49,997 tracked assignees

Innovation Score

37.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Celgene Quanticel Research, Inc.'s patent record in context - here's where to go next.

Celgene Quanticel Research, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 96.1% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #3,558 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Celgene Quanticel Research, Inc. against Weka.IO Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.